MTOR and non-small cell lung carcinoma: In lung cancer, anisamide-functionalized oligopeptide end-modified poly (beta aminoester) (OM-pBAE) nanoparticles selectively deliver mTOR siRNA to NSCLC, maintaining stability in serum, achieving efficient transfection, and suppressing tumor growth in vitro and in vivo with tumor selectivity [26].